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We investigated the clinical manifestations and course
of all probable severe acute respiratory syndrome (SARS)
patients in the Vietnam outbreak. Probable SARS cases
were defined by using the revised World Health
Organization criteria. We systematically reviewed medical
records and undertook descriptive statistical analyses. All
62 patients were hospitalized. On admission, the most
prominent symptoms were malaise (82.3%) and fever
(79.0%). Cough, chest pain, and shortness of breath were
present in approximately one quarter of the patients; 79.0%
had lymphopenia; 40.3% had thrombocytopenia; 19.4%
had leukopenia; and 75.8% showed changes on chest radi-
ograph. Fever developed on the first day of illness onset,
and both respiratory symptoms and radiographic changes
occurred on day 4. On average, maximal radiographic
changes were observed on day 10, and fevers subsided by
day 13. Symptoms on admission were nonspecific,
although fever, malaise, and lymphopenia were common.
The complications of SARS included invasive intubation
and ventilation (11.3%) and death (9.7%). 
T
he global outbreak of severe acute respiratory syn-
drome (SARS) has been epidemiologically linked to
an outbreak that is believed to have begun during
November 2002 in Guangdong Province, People’s
Republic of China (1). SARS then spread to other coun-
tries and regions, such as the Hong Kong Special
Administrative Region of China, Vietnam, Singapore,
Canada, and Taiwan. By the end of the outbreak, 26 coun-
tries had reported 8,098 probable cases of SARS and 774
deaths (2).
Coronavirus was first hypothesized to be the etiologic
agent of SARS by Peiris et al. (3). Later, two independent
teams (4,5) confirmed the novel coronavirus was associat-
ed with SARS infections in patients from Hong Kong,
Vietnam, Canada, and Taiwan. This article describes the
clinical and laboratory features of patients with SARS in
Hanoi, Vietnam. 
Methods 
Case Definition and Ascertainment
We used the World Health Organization (WHO) case
definition (April 1 revision) for SARS in this investigation
(6). A probable case-patient was defined as a person who
sought treatment after November 1, 2002, with a high
fever (>38°C) and cough or breathing difficulty and infil-
trates shown on chest radiograph consistent with pneumo-
nia or respiratory distress syndrome. A probable case-
patient was excluded if an alternative reason could fully
explain the illness, e.g., proven tuberculosis or clinical
response within 48 hours to antibacterial therapy. For prac-
tical purposes, we modified the case definition to only
include cases occurring on or after February 23, the date of
onset of symptoms of the Vietnam index case. Serologic
testing for SARS-associated coronavirus (SARS-CoV)
was performed on serum specimens as previously
described (4).
Case-patients were identified by clinicians, and consid-
erable effort was made by the Vietnam Ministry of Health
to train both metropolitan and rural staff in surveillance
and identification of SARS. Many case-patients were
admitted to hospital with suspected SARS; however, only
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The medical records of SARS case-patients were retro-
spectively reviewed by physicians. We used a standard-
ized data collection form to record patient information.
For the nine patients admitted to the hospital after March
20, clinical data were collected prospectively. For each
case-patient, clinical signs, symptoms, radiologic find-
ings, and data from biochemical, hematologic, and micro-
biologic tests throughout the course of illness were
recorded. When assessing the proportion of case-patients
with symptoms, if the information about a symptom was
not recorded, we assumed the symptom did not occur. For
the hematologic and biochemical course of illness, all
available measurements were used, with recordings for
>15 case-patients per day, and the measurements are dis-
played with accompanying standard deviation of means.
Onset of illness was defined as the date when each case-
patient first reported feeling unwell with symptoms com-
patible with SARS.
Data Analysis
Data from the medical records were entered into
Microsoft Excel and analyzed with Epi-Info version 6 soft-
ware. We analyzed the data by using standard descriptive
statistical techniques. To describe the course of the illness,
the maximum temperature, leukocyte count, platelet count
and lymphocyte count data from every case were com-
bined and averaged for each day of the illness.
Results 
The first SARS case-patient in Vietnam was admitted to
the hospital on February 26, 2003, and the last case-patient
was admitted on April 8, 2003. All 62 patients with proba-
ble SARS were admitted to hospitals in Hanoi, Vietnam.
The initial case-patients were admitted to a small private
hospital (hospital A), and the later case-patients were
admitted to a facility at a large public hospital, hospital B.
Of the 62 case-patients, 61 (98.4%) were seropositive for
SARS-CoV. The number of case-patients who were sus-
pected of having SARS but later excluded is not known.
Study Population
The mean age of SARS patients was 40.8 years (medi-
an 43, range 20–76 years) and 39 (62.9%) were female. A
detailed description of the epidemiology of the SARS out-
break in Vietnam will be published separately. 
Clinical Features 
Symptoms
The most prominent symptoms on admission were
malaise and myalgia (Figure 1). Less than one quarter of
the patients had symptoms of the lower respiratory tract on
admission; dry cough (22.6%), chest pain (24.2%), and
dyspnea (19.4%). The proportion of patients who reported
dry cough at any time throughout the illness increased to
90.3%. Other lower respiratory tract symptoms also
became more prominent after admission. Upper respirato-
ry tract symptoms were reported infrequently.
Signs
Fever was present at admission for 79.0% of case-
patients, with 66.1% having fever >38°C, although, as per
the case definition, all case-patients experienced fever dur-
ing their illness. Crepitations were present on admission in
35.5% of patients, and in 87.1%, crepitations developed
during the course of their illness. On admission, 47 (75.8%)
patients had abnormal chest radiographic results. The radi-
ographs of the remaining 15 case-patients showed abnor-
malities 2 to 7 days (median 5) from the admission date. 
On admission, the radiographic changes were mainly
interstitial infiltrates, bilateral or unilateral, affecting less
than two thirds of the lungs. Maximal radiographic
changes during the illness were mainly bilateral interstitial
infiltrates or bilateral alveolar opacities affecting more
than two thirds of both lungs. The degree of change on the
chest radiograph did not always appear to correlate with
the apparent severity of illness as defined by the need for
respiratory support. 
The mean white blood cell count on admission was
5.9 x 109/L, ranging between 2.7 and 16.3 x 109/L (Table).
Leukopenia was found in 19.4% of patients, and lym-
phopenia occurred in 79.3% of case-patients on admission,
with lymphopenia defined as total lymphocyte count
below 1.5 x 109 /L. Thrombocytopenia was observed in
40.3% of patients on admission, with a mean platelet count
of 160.7 x 109/L. 
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Figure 1. Symptoms of patients with probable severe acute respi-
ratory syndrome (N = 62), at hospital admission and reported dur-
ing the course of illness, Vietnam, February–May 2003. Note: All
case-patients had fever during their illness because this was part
of the case definition.Twenty-seven of the patients had biochemical blood
tests performed. For these patients, 34.5% had elevated
alanine aminotransferase levels, and 42.9% had abnormal-
ly high levels of aspartate aminotransferase. We observed
hyponatremia in 29.6% of patients on admission, and
14.8% of patients had hypokalemia.
Natural History of Illness
The average maximum temperature for all of the case-
patients on day 1 of onset was 38.7°C and reached a max-
imum of 39.0°C on day 5 (Figure 2). We observed that
fever in SARS patients subsided on day 13. Overall, the
average leukocyte count of all the cases never decreased
below 4.0 × 109/L, suggesting that leukopenia was not a
common feature of SARS among the whole cohort, but did
occur in a few patients, as indicated by the error bars on
Figure 2. Thrombocytopenia (platelet count < 150 × 109/L)
was present in the cohort from day 4 until day 9 of the ill-
ness. After day 10, the average platelet count returned to
within the normal range. Lymphopenia (lymphocyte count
<1.5 × 109/L) was present throughout the course of the ill-
ness, with lymphocyte counts ranging from 1.0 to 1.5 ×
109/L.
The natural history of SARS in Vietnam is shown in
Figure 3. Not all patients felt feverish at onset, but fever
developed an average of 0.3 days after the onset of other
SARS symptoms. We observed that the average length of
time from onset to observed radiographic changes and
from onset to first respiratory symptoms were similar
(4.4–4.8 days) and generally coincided with admission to
hospital. Maximal radiographic changes occurred on the
10th day of illness, on average, 3 days before fever sub-
sided. SARS patients were in hospital for, on average, 24.5
days (± 7.4 days). A total of six (9.7%) case-patients died.
We observed that the time from symptom onset to admis-
sion decreased during the outbreak (data not shown).
Case Management
Respiratory Therapy
Respiratory assistance was required for 38 (61.2%) of
the patients: 25 (40.3%) patients required the use of sup-
plemental oxygen; 6 (9.7%) required positive pressure
noninvasive ventilation while an additional 7 (11.3%)
patients were intubated and received mechanical ventila-
tion. Only 1 of the 7 who were intubated recovered. 
Antibiotics
A wide range of antibiotics were prescribed for SARS
patients in Vietnam, including beta-lactams, tetracyclines,
aminoglycosides, macrolides, and fluoroquinolones.
Antibiotic therapy was not observed to be clinically bene-
ficial. 
Antivirals
Patients in the first wave of the outbreak of SARS were
initially treated with oseltamivir when the etiologic agent
was thought to be an influenza virus. Eighteen patients
(29.0%) received oral or intravenous ribavirin for an aver-
age of 9 days (median 12 days) after the onset of illness.
Neither oseltamivir nor ribavirin was observed to have any
clinically beneficial effect on the course of illness.
Steroids
For 14 patients, steroid treatment was begun an average
of 8.2 days after the onset of illness (median 7 days).
Patients were given steroids for a mean duration of 7.6
days (range 1–14 days). No particular protocol existed for
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Table. Hematologic and biochemical features of patients with severe acute respiratory syndrome on admission 
Range  Abnormal 
Parameter  Low  High  Mean  Median  Normal range  % Low  % High  N 
Leukocytes (× 10
9/L)  2.7  16.3  5.9  5.3  4–10  19.4  6.5  62 
Neutrophils (%)  44.0  92.8  70.7  71.0  40–75  –  37.1  62 
Lymphocytes (%)  4.7  50.0  22.4  22.0  20–45  38.7  3.2  62 
Lymphocyte count (× 10
9/L)  0.3  2.2  1.1  1.1  >1.5  79.3  –  58 
Hemoglobin (g/L)  88  216  132.4  132.0  125–155  25  1.7  60 
Hematocrit (%)  27.3  46.8  38.8  38.6  40.0–52.0  25  1.7  60 
Platelets (× 10
9/L)  53  293  160.7  158.0  150–450  40.3  –  62 
C-reactive protein (mg/L)  1  136  24.7  17.0  0–8  –  75  44 
Alanine aminotransferase (UI/L)  
Hospital A  
Hospital B 
 
8.0 
13.0 
 
36.0 
294.0 
 
22.3 
70.0 
 
22.0 
49.0 
 
10–50 
<40 
3.4  34.5 
 
12 
17 
Aspartate aminotransferase (UI/L)  
Hospital A 
Hospital B 
 
23.0 
19.0 
 
89.0 
550.0 
 
43.7 
101.0 
 
38.0 
57.0 
 
10–50 
<37 
–  42.9 
 
11 
17 
Sodium (mmol/L)  129  148  137.1  138  135–145  29.6  3.7  27 
Potassium (mmol/L)  3.3  4.7  3.9  3.9  3.5–5.0  14.8  –  27 
Creatinine (mg/L)  48  133  93.2  93.0  5.6–12.4  4.5  9.1  22 the timing or dosage of steroids given, making interpreta-
tion of effectiveness difficult. 
Discussion
This is the first report of a complete outbreak of SARS
and as such includes all patients in whom SARS was diag-
nosed from the beginning of the outbreak until SARS was
declared contained in Vietnam on April 28, 2003. Dr Carlo
Urbani (deceased), a public health physician with WHO in
Vietnam, first described the outbreak in reports to WHO at
the beginning of March 2003. He reported a similar pres-
entation of case-patients that we describe. The main clini-
cal features of probable SARS case-patients reported in
Vietnam were fever, malaise, dry cough, and infiltrates on
radiographs. These findings are consistent with those
reported in Hong Kong (3,7), Singapore (8), and Canada.
(9) Additionally, we have described the clinical develop-
ment of SARS over time. The main feature exhibited by
SARS case-patients on hospital admission was fever,
which typically lasted 13–14 days after onset. 
Lymphopenia was constant throughout the illness and
thrombocytopenia, on average, lasted for 5 days, begin-
ning on the fourth day after onset. Respiratory symptoms
and the first radiographic changes were first noted on day
4 of the illness. Maximal radiograph change generally
occurred on day 10. 
On admission, 6.5% of patients reported having diar-
rhea. However, patients with SARS may have recalled res-
piratory symptoms more frequently than gastrointestinal
symptoms. During the full course of illness, half of the
probable SARS case-patients reported diarrhea. What pro-
portion of these patients had diarrhea directly related to
SARS or in response to antibiotic treatment is not known.
Diarrhea, regardless of its cause, has important implica-
tions for transmission of SARS, because SARS-CoV can
be shed in feces(10). However, it is not yet known whether
viable organisms are shed in quantities sufficient to consti-
tute a substantial source for transmission. The role of diar-
rhea in SARS transmission requires further investigation. 
Our data on clinical symptoms at admission may not be
generalizeable to other SARS outbreaks for several rea-
sons. Admission bias may have occurred at hospital Aafter
the initial cluster among healthcare workers was recog-
nized. In some instances, temperatures were being taken
and some patients were admitted after fever onset but no
other symptoms, daily chest x-rays were taken for some
case-patients, and some patients refused admission until
after they had been ill for several days. 
Microbiologic evaluation of patients who met the case
definition for probable SARS in Vietnam was difficult at
the time of admission. Decisions about case status on
admission were initially made by considering clinical signs
and symptoms. We did not have laboratory facilities to con-
firm SARS, and facilities to identify other agents causing
atypical pneumonia were limited. Patients were treated
with antibiotics for atypical bacterial pneumonia on admis-
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Figure 2. Average (±1 standard deviation) maximal daily tempera-
ture, leukocyte count, platelet count, and lymphocyte count by day
of severe acute respiratory syndrome from onset, Vietnam,
February–May 2003, (N = 62 cases but not for each data point).
Figure 3. Average (±1 standard deviation) duration of time from
onset of illness until outcome in the evolution of severe acute res-
piratory syndrome, Vietnam, February–May 2003sion to hospital, and if the patients responded to treatment
within 48 hours, the SARS case status was revised. 
All case-patients with probable SARS in the Vietnam
outbreak were epidemiologically linked, and 98.4% had
serologic evidence of SARS-CoV infection. After the ini-
tial case, all probable SARS cases identified in the
Vietnam outbreak were among healthcare workers or close
contacts of case-patients. 
Our findings in regard to treatment are nonspecific.
Proven treatment options must await proper clinical trials
in other centers. 
Despite the nonspecific nature of SARS at clinical pres-
entation, a typical case had fever, myalgia, malaise fol-
lowed several days later by cough and respiratory symp-
toms. At this point the patient typically had changes shown
by chest x-ray, lymphopenia, and thrombocytopenia. Due
to the nonspecific nature of SARS, both on admission and
throughout the course of illness, clinicians must obtain a
detailed exposure history for anyone presenting with atyp-
ical pneumonia to help in the early diagnosis and manage-
ment of a potential outbreak situation. When the diagnosis
is in doubt, the person should be isolated under strict infec-
tion control procedures until the diagnosis becomes clear. 
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